Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Amortizatization of Intangibles (2021 - 2025)

Historic Amortizatization of Intangibles for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $2.3 million.

  • Prime Medicine's Amortizatization of Intangibles rose 466.37% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 3106.34%. This contributed to the annual value of $12.4 million for FY2024, which is 338.6% down from last year.
  • Per Prime Medicine's latest filing, its Amortizatization of Intangibles stood at $2.3 million for Q3 2025, which was up 466.37% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Amortizatization of Intangibles registered a high of $4.6 million during Q2 2024, and its lowest value of $1.4 million during Q4 2021.
  • Over the past 5 years, Prime Medicine's median Amortizatization of Intangibles value was $2.6 million (recorded in 2022), while the average stood at $2.7 million.
  • In the last 5 years, Prime Medicine's Amortizatization of Intangibles soared by 10231.38% in 2022 and then crashed by 4861.02% in 2025.
  • Quarter analysis of 5 years shows Prime Medicine's Amortizatization of Intangibles stood at $1.4 million in 2021, then surged by 102.31% to $2.8 million in 2022, then rose by 19.66% to $3.3 million in 2023, then plummeted by 34.05% to $2.2 million in 2024, then grew by 5.71% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.3 million for Q2 2025, and $2.4 million during Q1 2025.